Clinical development of crispr-CAS3 phage cocktail for the treatment of recurrent urinary tract infections caused by escherichia coli including antimicrobial and multi-drug resistant strains

Active Definitive Contract Awarded Last action

Contract number
75A50120C00169
Awardee
Awarding agency
Obligated
$73,885,104

Award facts

Opportunity
Contract value 67% obligated
  • $73,885,103.73 Current, with exercised options
  • $109,817,550.73 Potential, with all options
Completion date 97% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing
Place of performance
Morrisville, NC, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00009 · The purpose of this bilateral modification is to: 1. Add $14,773,583.00 of supplemental funding to clin 0002. 2. Add $3,226,417.00 of supplemental funding to… $18,000,000
Other Administrative Action P00008 · The purpose of this bilateral modification is to: 1.supplementally fund clin 0003. 2.update key personnel. 3.extend period of performance for clins 0002 and… $6,938,671
Exercise an Option P00007 · The purposes of this modification are to 1. Exercise option period 1 clin 0002 with a period of performance of january 19, 2024 to september 30, 2025. 2.… $23,887,629
Supplemental Agreement for work within scope P00006 · The purposes of this bilateral modification are to: 1) add $7,809,935.00 under the base period clin 0001 with a period of performance of september 28, 2022 ?… $7,809,935
Other Administrative Action P00005 · The purpose of this no cost, bilateral modification is to: a.) update article B.2, base period to update the POP of clin 0001. B.) the period of performance for… $0
Exercise an Option P00004 $6,240,948
Change Order P00003 $0
Change Order P00002 · Advance the development of crphage as a crispr-engineered precision antibacterial of urinary tract infections caused by E. Coli. $0
Other Administrative Action P00001 · Administrative MOD to change COR $0
Original award $11,007,921

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded Locus Biosciences Inc. a definitive contract valued at approximately $109.8M to support clinical development of a CRISPR-Cas3 phage cocktail for treating recurrent urinary tract infections caused by Escherichia coli, including antimicrobial-resistant and multi-drug-resistant strains. This bilateral modification added $14.8M in supplemental funding to CLIN 0002 and $3.2M to CLIN 0003, reflecting the government's commitment to advancing this novel bacteriophage-based therapeutic toward FDA approval. The contract employs cost-sharing pricing and is scheduled for completion by January 1, 2027, with performance occurring at Locus Biosciences' facility in Morrisville, North Carolina. No set-aside designation was applied to this award.

This effort originated from a Broad Agency Announcement posted by the Biomedical Advanced Research and Development Authority in October 2017, which solicited proposals for advanced research and development of medical countermeasures against biological and other emerging threats. Locus Biosciences, a clinical-stage biopharmaceutical company specializing in engineered bacteriophage therapeutics, was selected to develop innovative antibacterial solutions targeting serious drug-resistant bacterial infections. The company's focus on creating bacteriophage cocktails capable of addressing infections resistant to traditional antibiotics aligns with BARDA's mission to advance candidates toward FDA approval and addresses a significant public health need, particularly given that engineered phage therapies represent a novel approach to treating multidrug-resistant urinary tract infections.

Quick answers

Who was awarded contract 75A50120C00169?

75A50120C00169 was awarded to Locus Biosciences Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 28, 2020.

How much is contract 75A50120C00169 worth?

The government has obligated $73,885,104 on 75A50120C00169. Its potential value, with all options, is $109,817,551.

Was contract 75A50120C00169 competed?

The extent of competition for 75A50120C00169 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login